Market News & Trends
Aegerion Pharmaceuticals Submits US & EU Marketing Applications
Aegerion Pharmaceuticals, Inc. recently announced it has submitted an NDA to the US FDA and an MAA to the EMA seeking approval of Aegerion's lead…
CiToxLAB Increases Inhalation Test Capabilities
CiToxLAB recently announced it has increased its inhalation test capabilities in North America and Europe. The demand for studies to assess the safety of pharmaceuticals…
Lipid Therapeutics Licenses European Rights to its Lead Product
Dr. Falk Pharma GmbH and Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, recently announced they have entered into a…
Mersana Therapeutics Strikes $270 Million Antibody-Drug Conjugate Deal
Mersana Therapeutics, Inc. recently announced it has entered into a collaboration agreement with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs). Mersana's proprietary conjugation technology…
Particle Sciences Acquires Exclusive License to Lyotropic Therapeutics' Delivery Technology
Particle Sciences, Inc. (PSI) and Lyotropics Therapeutics, Inc. recently announced PSI has acquired the exclusive rights to the Lyotropics' LyoCell patent portfolio. The LyoCell technology allows…
3/6/2012
Avanir & Concert Announce Exclusive License Agreement Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into an exclusive license agreement that…
Absorption Systems' Innovation Rewarded With New US Patent for CellPort Technologies
Absorption Systems recently announced a new US patent issued on January 31 that protects intellectual property around its P-glycoprotein (P-gp) knockdown cell line within the…
Aptar Unveils Innovative Delivery Devices for the Future
Aptar Pharma, a world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, recently announced it had presented its latest innovation,…
Avanir & Concert Announce Exclusive License Agreement
Avanir Pharmaceuticals, Inc. and Concert Pharmaceuticals, Inc. recently announced they have entered into an exclusive license agreement that provides Avanir worldwide rights to develop and…
Haselmeier Establishes New Pen Injector Assembly Facility
Haselmeier, a leading designer and manufacturer of pen injection systems, recently announced it will establish a new manufacturing facility in Bangalore, India, to produce and…
Neuronex Announces $100-Million Merger Agreement
Neuronex recently announced the signing of a merger agreement with Acorda Therapeutics that, if completed, would result in full acquisition by Acorda and potential payments…
2/21/2012
Catalent Pharma Solutions & NewMarket Sign Development Agreement Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly…
Catalent Pharma Solutions & NewMarket Sign Development Agreement
Catalent Pharma Solutions and NewMarket Pharmaceuticals LLC recently announced they have entered into an agreement to jointly formulate and develop a portfolio of products for…
Curis & Debiopharm Announce Initiation of Phase Ib Expansion Study
Curis, Inc. and Debiopharm Group recently announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90 (HSP90)…
DARA BioSciences Signs Exclusive Agreement With Uman Pharma
DARA BioSciences, Inc. recently announced it entered into an exclusive US agreement with Uman Pharma Inc. for commercial rights to gemcitabine, DARA's second newly licensed…
IntelGenx Announces License Agreement With Edgemont Pharmaceuticals
IntelGenx Corp. recently announced it has entered into an exclusive agreement with Edgemont Pharmaceuticals, LLC for the commercialization of IntelGenx's lead product CPI-300 in US.…
Malvern & Postnova to Deliver Solution for Characterizing Challenging Particulate Systems
Malvern Instruments and Postnova Analytics recently announced they are co-operating to deliver the combined FFF (Field-Flow Fractionation) and DLS (Dynamic Light Scattering) solutions that today…
Sandoz Buys Rights to Apricus Biosciences' Drug for $28 Million
Apricus Biosciences, Inc. recently announced its wholly owned subsidiary NexMed, Inc. has signed with Sandoz, a division of Novartis, an exclusive collaboration for Germany to…
CHEMO & Particle Sciences Partner to Provide the Only Development-to-Commercialization Solution
Particle Sciences Inc. and CHEMO recently announced they have formed a partnership to offer complete contract product development and commercial manufacturing of hormone-eluting devices. Particle Sciences…
Cytomedix Acquires Aldagen
Cytomedix, Aldagen, acquisition details, 5 million dollar stock purchase, PRP platform technology, Martin Rosendale, cell selection technology Cytomedix, Inc. recently announced the completion of the…
